Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as executive Vice President, Head of Research and Development

By WebmasterMarch 9, 2020November 1st, 2024No Comments

Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as executive Vice President, Head of Research and Development

Previous PostRelmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
Next PostPalvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita